Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China
This study has been completed.
Study NCT01491087   Information provided by Sanofi

First Received on December 9, 2011.   Last Updated on March 28, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Diphtheria
Tetanus
Pertussis
Polio
Additional conditions recognized in this trial
Poliomyelitis
Whooping Cough
More general conditions related to this trial
Actinomycetales Infections
Bacterial Infections
Bordetella Infections
Central Nervous System Diseases
Central Nervous System Infections
Central Nervous System Viral Diseases
Clostridium Infections
Corynebacterium Infections
Enterovirus Infections
Gram-Negative Bacterial Infections
Gram-Positive Bacterial Infections
Infection
Myelitis
Nervous System Diseases
Neuromuscular Diseases
Picornaviridae Infections
Respiratory Tract Diseases
Respiratory Tract Infections
RNA Virus Infections
Spinal Cord Diseases
Virus Diseases
Sponsors listed in this trial
Sanofi Pasteur, a Sanofi Company


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services